drugset
drugset / Trial / NCT03040973

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973 ↗

Phase 2 Active not recruiting 29 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study

Timeline

Start
2017-08-23
Primary completion
2027-07-30
Completion
2027-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Capmatinib Small molecule 150 mg Oral
Subject Capmatinib Small molecule 200 mg Oral
Subject Gefitinib Small molecule 250 mg Oral
Subject Nazartinib Small molecule 25 mg Oral
Subject Nazartinib Small molecule 50 mg Oral
Subject Osimertinib Small molecule 40 mg Oral
Subject Osimertinib Small molecule 80 mg Oral

Indications

No indication recorded.